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SYNTHESIS AND METHYLATION OF NUCLEAR RNA IN L1210
MOUSE LEUKEMIA CELLS
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Fulfillment of the Requirement for the degree of Doctor of Medicine 1982.

Henry J. Stern

ABSTRACT
Three adenosine analog antitumor agents,

tubercidin,

formycin,

and

8-azaadenosine were investigated for their affects on the synthesis and
methylation of nuclear RNA (nRNA)

in L1210 mouse leukemia cells in Vitro.

Tubercidin inhibited both total RNA and DNA synthesis

to

the greatest

extent (IC^q = 7 X 10"^M) as determined by filtration assay.
These
effects were not potentiated by the adenosine deaminase inhibitor
2'-deoxycoformycin (dCF).
Formycin and 8-azaadenosine demonstrated
negligible inhibition in the absence of dCF; however, 1 X 10-^M formycin +
dCF and 1 X 10~^M 8-azaadenosine 4- dCF each inhibited RNA synthesis by
40%,

both agents showing preferential inhibition of RNA vs DNA synthesis.

DEAE Sephadex-Urea chromatography of alkaline hydrolysates of nRNA
double-labeled with L-[methyl-^H] methionine and [
C] uridine demonstrated
preferential inhibition of base methylation relative to nRNA synthesis
for all three drugs.
methylation.

This effect was not observed for 2'-0-ribose

Using denaturing polyacrylamide gel electrophoresis,

tubercidin was shown to preferentially inhibit methylation relative to [
uridine incorporation in both >18S nRNA and 4S nRNA;

however,

^
C]

formycin

and 8-azaadenosine demonstrated selective preferential inhibition of
methylation relative to nRNA synthesis for 4S nRNA and >
respectively.

18S nRNA

Both tubercidin and formycin preferentially inhibited

the synthesis of 4S nRNA while 8-azaadenosine showed no consistent
dose response for selective inhibition of the synthesis of either 4S
nRNA or >18S nRNA.
Two dimensional thin-layer chromatography of
enzymatically digested 4S nRNA revealed that the observed inhibition
of base methylation was associated with reduced methylation of seven
of the eight methylated nucleosides commonly found in 4S nRNA, with
each drug apparently inhibiting a unique spectrum of RNA methyltransferases.
These differential effects of tubercidin,

formycin,

and 8-azaadenosine

on nRNA synthesis and methylation showed no consistent relationship with
their glycosyl bond lengths or torsion angles.
The results of this
investigation indicate that tubercidin, formycin, and 8-azaadenosine
can inhibit nRNA methylation, and the hypothesis in proposed that this
effect may be

related to their antitumor properties via the production

of defectively methylated RNA which subsequently undergoes maturation
arrest and degradation.
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INTRODUCTION:
In this study the effects of tubercidin,

8-azaadenosine,

and

formycin on nuclear RNA synthesis and methylation in L1210 mouse
leukemia cells is investigated

(Stern,

structurally related to adenosine,
portion of

the purine ring of

1980).

These compounds,

differ only in the imidazole

the parent compound

(Fig.

I).

Recent

advances in molecular genetics have implicated that methylation of
RNA is important in the processing of this informational macromolecule.
That RNA methylation and neoplasia may be related comes from studies
showing that certain neoplastic tissues have increased tRNA methylase
capacity

(Borek,

1972).

By investigating the effects of these

structurally similar adenosine analogs on this important biological
process,

it is hoped that structure activity correlates can be deduced

that maybe useful in the rational design of future antineoplastic agents.
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-PART ONE-

CELLULAR METABOLISM AND ANTITUMOR PROPERTIES OF TUBERCIDIN,
FORMYCIN,

AND 8-AZAADENOSINE

1

TUBERCIDIN
Tubercidin,
also known as

4-amino-7-(B-D-ribofuranosyl)

pyrrolo

[2,3-d]

pyrimidine,

7 deazaadenosine is a pyrrolopyrimidine nucleoside

antibiotic isolated from the broth of Streptomyces tubercidicus
(Anzae,

1957).

The glycosyl bond length of tubercidin is 1.44 A,

than the glycosyl bond of adenosine which is 1.47A
also found that the glycosyl
which describes
crystal of

torsion angle X:

Abola

0-C(1’)-N(9)-C(8)

Normally purines exist in the anti

Although in the solid state tubercidin

occurs in the anti conformation,

its 5'

1973).

shorter

conformation and it is this conformation that is required

for normal duplex formation.

(X= 210 + 45°)

(Abola,

I)

the relative orientation of the sugar to the base of a

tubercidin to be 73.0.

(X= 30 + 45°)

(Fig.

in aqueous solution both syn

and anti conformations were obtained by tubercidin and

phosphate

(Evans,

1975).

Tubercidin is classified along with

formycin and 8-azaadenosine as having a glycosyl torsion angle in the
high anti range,
(Singh,

1977).

intermediate between the classical anti and syn regions
As will be discussed below,

the steric conformation of

these analogs is important in determining their biochemical properties.
The in Vitro cytotoxicity of tubercidin was quickly established for
NF mouse sarcoma,
and Earles L cells
faecalis,

human epidermoid carcinoma
(Duvall,

1962).

(KB),

Ehrlich ascites cells,

Unlike studies using Streptococcus

cytotoxicity in the KB system was not reversible with purine

or pyrimidine nucleosides of nucleotides

(Smith,

1967;

Bloch,

1967).

Vivo cytotoxicity studies were also performed where toxicity to

2

In

the lung,

pancreas, kidneys, liver, and gonads was observed following intravenous
administration of tubercidin (Owen, 1964).

It was found that of 25 tumors

tested tubercidin was confirmed to be active at non toxic doses against
mice with ascitic sarcoma 180, Ehrlich asciti.es tumor, and Jensen sarcoma.
Leukemia L1210 was not affected by tubercidin treatment.
Because of these encouraging results phase I trials were undertaken.
In 1970 Bisel et al selected 93 patients with a neoplastic spectrum
including lung, kidney, sarcoma, colon, rectum, breast, head and neck,
pancreas, melanoma, ovary, cervix, and stomach and administered intravenous
tubercidin in a dose of 0.025 mg/kg/day, increasing this to 0.3 mg/kg/day
in the absence of toxicity (Bisel,
lasted for 10 consecutive days.

1970).

Such a course of treatment

Nephrotoxicity, manifested by proteinuria

and azotemia, was observed in 18 cases with thrombophlebitis in 12.
3
Leukopenia to 2900-4500 leukocytes/mm

occurred in 6 patients.

Only

three patients showed a response, 1 subjective and 2 both subjective and
objective as assessed by a decrease in size of an intra-abdominal mass.
All three had primarly pancreatic carcinoma of the islet cell type.
There were six such patients studied.
In an effort to avoid the problem of thrombophlebitis caused by
IV administered tubercidin, it was observed that 80%-98% of tubercidin
is absorbed by red blood cells (Smith, 1970).

Most of the absorbed

tubercidin exists intracellularly in the triphosphate form.

There was

no decrease in tubercidin loaded RBC survival as assessed by ~*"*~Cr tag
experiments.

When administered by rapid TV injection to dogs,

3

25% of

the drug appeared in the urine in 24 hours,

but when red blood cells

were used as a vehicle only 18% appeared in the urine in 21 days.

These

results were exploited by Grage who removed 300-500 ml of blood/patient,
saturated it with tubercidin,

and retransfused it at weekly intervals

for 2 doses ranging from 200ug/kg to 1500 ug/kg in the 45 patients
studied in his phase I trial
served.

(Grage,

Six cases of hematologic

1970).

toxicity,

No thrombophlebitis was
5 renal,

ob¬

2 hepatic, and 1

case of severe gastrointestinal toxicity were noted and there was no
correlation with increased dose and the number of patients experiencing
toxicity.

Of the patients studied 4 had an objective regression,

3

islet cell cancers and 1 metastatic stomach carcinoid to the cervical
lymph nodes.

It is of interest that in animal studies disappearance of

the islets of Langerhans is consistently found in tubercidin treated
animals,

and it is this selective toxicity that may make tubercidin

valuable in current chemotherapeutic protocols.
Group Protocol 7230A combines

tubercidin,

The Central Oncology

streptozotocin,

and 5-flourouracil

whereby tubercidin is mixed with 500 ml of the patient’s blood and
retransfused over a four hour period in a dose of 1.5 mg/kg of body weight.
5-Flourouracil at 12.5 mg/kg is given the same day and for an additional
two days.

After a 7-day rest period streptozotocin is added in a dose

of 12.5 mg/kg in weekly doses alternating with 12.5 mg/kg of 5-flourouracil
for the next six weeks.

After a four week rest period the regimen is

repeated if the hematologic picture is satisfactory.

This protocol was

valuable in treating 5 patients with extensive gastrinoma,

4

all patients

feeling better and gaining from 3-35 pounds

(Zollinger,

1976).

Two of

four patients with advanced islet cell carcinoma showed a dramatic
initial response with the other two demonstrating prolonged survival on
this protocol

(Kraybill,

1976).

In a four year study beginning in 1972,

105 patients with adenocarcinoma or islet cell carcinoma of

the pancreas

were treated with the Central Oncology Group Protocol or 5-flourouracil
alone

(Awrich,

1979).

The results indicated that for adenocarcinoma

of the pancreas there was no significant difference in survival or time
to progression of disease when these two

treatments were compared.

Eight patients with islet cell tumors were treated with the Central
Oncology Group Protocol only with none experiencing progression of the
disease and three demonstrating a partial response, where a partial
response was defined as a 50% reduction in the product of the diameters
of the lesions.
Another example of the clinical efficacy of tubercidin is in the
treatment of solitary nodular basal cell carcinoma

(Burgess,

1974).

Eight patients with this disorder were treated with a 0.5% ointment of
tubercidin with all showing clinical disappearance of

the tumor

confirmed by biopsy and negative recurrence at 1 1/2 years post treatment.
No signs of systemic toxicity were observed.

Similar results were

obtained by Klein, who in addition found higher doses of

tubercidin

ointment of value in the treatment of mycosis fungoides,

reticulum

cell sarcoma,

squamous cell carcinoma, and soft tissue metastases of

carcinoma of the breast

(Klein,

1975) .

The mechanism of the cytotoxicity of tubercidin has been investigated

5

on many different levels.
synchronized DON cells,

Tubercidin has been shown to be cytotoxic to

isolated from a Chinese hamster fibroblast line,

in all phases of the cell cycle at low dose, while at higher doses cells
at the Gl-S boundry appeared more sensitive
on DNA,

RNA,

(Bhuyan,

1972).

Studies

and protein synthesis using low dose tubercidin revealed

marked inhibition in the synthesis of all these molecules,
and 88% inhibition respectively.

84%,

86%,

Simultaneous inhibition of DNA,

RNA,

and protein synthesis was also observed to occur in another mouse
fibroblast line

(Acs,

1964).

This author also observed certain cytologic

changes when the cells were exposed to tubercidin.

These changes did

not occur when the cells were pretreated with actinomycin.

This is an

interesting result in lieu of the data obtained by Bhuyan which suggests
increased sensitivity of cells

to tubercidin at a time in the cell cycle

dominated by RNA transcription.
Further insight into the biochemical basis of the cytotoxicity of
tubercidin comes from work with sublines of human epidermoid carcinoma
(H.Ep.#2)

cells with deficiencies in adenosine kinase,

a subline with

a combined deficiency in adenosine kinase and hypoxanthine-guanine
phosphoribosyl transferase

(HGPRT),

and another line with a combined

deficiency in adenosine kinase and adenine phosphoribosyl transferase
(APRT).

By determining the sensitivities of

these sublines

to an array

of purine ribonucleoside analogs it was deduced that the three pathways
illustrated in (Fig.

II)

could be utilized by these compounds in gaining

entrance into the nucleotide pool

(Bennett,

6

1966) .

Tubercidin was

shown to utilize pathway I,

involving adenosine kinase,

anabolic pathway although pathway II,
and APRT is also used,

as its major

involving nucleoside phosphorylase

albeit to a much lesser degree.

Confirming this

were studies demonstrating that tubercidin is in fact a substrate not
only for adenosine kinase from H.Ep.#2 cells,
faster than adenosine,

being phosphorylated 4X

but for adenosine kinase isolated from yeast and

sarcoma 180 cells as well

(Schnebli,

1967;

Bloch,

1967).

Data showing

that mouse fibroblasts are insensitive to the aglycone of tubercidin,
and that adenosine phosphorylase and APRT isolated from extracts of
jS.

faecalis did not utilize tubercidin also suggests

not a major anabolic pathway

(Acs,

1964;

Bloch,

that pathway II is

1967).

Interestingly,

pathway III was shown to be the major metabolic pathway for adenosine in
this cell system.

It is no surprise that tubercidin is not metabolized

via pathway III since this adenosine analog has been shown not to be a
substrate for adenosine deaminase
human erythrocytes,
1975;

Adamson,

(ADA)

purified from intestinal mucosa,

or P388 murine leukemia cells

1977).

without 2’deoxycoformycin
(Ki = 2.5 X 10

Agarwal,

(dCF),

-12

the same degree, with or

a competitive inhibitor of adenosine

M for human erythrocyte ADA).

of the acid soluble pool of mouse fibroblasts exposed to
revealed 5-10% Tu5'MP,

8-15% Tu5'DP,

analogs detected

1964).

(Acs,

1967;

Adamson demonstrated that tubercidin inhibited

the growth of P388 murine leukemia cells to

deaminase

(Bloch,

Characterization
tubercidin

and 75-85% Tu5'TP, with no guanine

It is perhaps the inability of tubercidin

to be metabolized via pathway III

that accounts for its lack of conversion

7

to guanine nucleotides.
Numerous studies have demonstrated that tubercidin not only becomes
a member of the nucleotide pool but perturbs

that pool as well.

Bloch

demonstrated that tubercidin interfered with the formation of ATP from
AMP in both the sarcoma 180 and J3.

faecalis systems,

a result confirmed

in mouse leukemia EL4 cells where up to 80% of cellular ATP was lost
with a concomitent build up of tubercidin triphosphate and its 3'5’
analog

(Bloch,

1967;

Zimmerman,

1978).

cells,

tubercidin was as effective as adenosine in producing a 50%

cyclic

Using azaserine treated H.Ep.#2

reduction in formylglycinamide ribonucleotide and ribonucleoside levels
(Bennett,

1964).

This result was investigated further in Ehrlich ascites
14

tumor cells

in Vitro, whereby using ribonucleotide synthesis from

l

,
CJ

adenine as a measure of the rate of 5 phosphoribosyl-l-pyrophosphate
(PRPP)
1965) .
inhibit

synthesis,
Therefore,

tubercidin was shown to inhibit PRPP synthesis

(Henderson,

while tubercidin has been shown by several studies

de novo purine biosynthesis in a variety of systems,

of this inhibition appears

to

the site

to be phosphoribose pyrophosphokinase and

not amidophosphoribosyl transferase as one would have guessed.
Evidence that tubercidin is capable of entering the deoxyribonucleotide
pool comes from studies where tubercidin was used as a substrate and
allosteric modulator for prokaryotic ribonucleotide reductase.
ribonucleotide reductase,

E.

Coli

which reduces ribonucleoside diphosphates

using dGTP and TTP as positive allosteric modulators,

acted on tubercidin

diphosphate with 40% of the activity demonstrated for ADP, with dGTP
but not TTP serving as a positive allosteric modulator

8

(Chassy,

1968).

Unlike the EL

Coli enzyme,

ribonucleotide reductase from Lactobacillus

leichmanii utilizes ribonucleoside triphosphates with dGTP and 2’dATP
as "prime effectors"

(Suhadolnik,

1968).

Tubercidin triphosphate

reduction was 75% of ATP with dGTP acting as a better positive modulator
than 2’dATP for this reduction.

In addition to

this,

tubercidin

triphosphate was found to be 50% as effective as 2'dATP as a positive
allosteric modulator for CTP reduction.
modulator for ATP reduction,
effect.

While 2’dATP is a negative

tubercidin triphosphate had a negligible

The results of these studies indicate that at least in prokaryotes

tubercidin is a substrate for reduction to its deoxy analog,
precursors for incorporation into DNA,

supplying

and that tubercidin can interact,

albeit in a modified way with the regulatory site of this enzyme.
As has been reviewed above,

tubercidin is able to enter the

nucleotide pool and can be converted to deoxy as well as mono,
triphosphate forms.

Evidence exists

di,

and

that these nucleotide precursors

are capable of entering anabolic pathways used in the formation of
nucleotide containing cofactors as in the case of nicotinamide-deazaadenine dinucleotide isolated from tubercidin treated S_.
(Bloch,

1967).

faecalis

Tubercidin incorporation into DNA and RNA has been

established in bacteria,

mouse fibroblasts, mouse L5178y cells,

single stranded RNA Mengo virus

(Bloch,

1967; Acs,

1964;

and the

Seibert,

1978).

Seibert demonstrated that with L5178y cells treated with a dose of
tubercidin of 0.05ug/ml 21% is incorporated into acid insoluble material
with 15% of the tubercidin incorporated distributed into DNA and 84%

9

into total RNA.

Acs,

using tubercidin at a dose of 1 ug/ml to

mouse fibroblast L cells,

treat

found a total incorporation of tubercidin

into acid insoluble material of only 5% with a distribution of tubercidin
into RNA 2.7X that of DNA

(Acs,

1964).

It appears then that incorporation

of tubercidin into acid insoluble material varies with the cell system
studied,

and that tubercidin appears

to accumulate in RNA to a greater

extent than DNA.
Several studies have demonstrated that tubercidin interferes with
RNA transcription and processing.

This evidence will be presented

later.

10

FORMYCIN
Formycin A or 7-amino-3-(B-D-ribofuranosyl)-pyrazolo

[4,3-d]

pyrimidine was originally isolated from culture filtrates of Nocardia
Interforma
formycin

(Hori,

1964).

As can be seen from

(Fig.

I),

(formycin will be used to refer to formycin A)

the structure of
is similar to

adenosine except that C8 and N9 have been interchanged causing an
increase in the length of this CC glycosyl bond to 1.55 A (Ward and
Reich,

1968).

The glycosyl torsion angle is 109.5, much larger than

the angle for tubercidin,
configuration

(Prusiner,

but like tubercidin exists in a high anti
1973).

The absence of the C8 hydrogen, which

in adenosine interacts with the furanose ring to decrease rotation,
combined with this

increase in glycosyl bond length,

allows for freedom

of rotation in this adenosine analog not observed in the parent compound.
Formycin has been shown to be a substrate for P388 murine leukemia adenosine
deaminase,

being deaminated to the inosine analog formycin B

with a Km and Vmax larger than adenosine

(Adamson,

1977) .

(Fig.

Ill),

Adenosine

deaminase isolated from calf intestines has been shown to accept substrates
only in the anti conformation and the increased Km observed for formycin
may be explained by the conformation of this analog which is intermediate
between syn and anti

(Ogilvie,

1971) .

Presumably the freedom of rotation

around the glycosyl bond allows formycin to adopt the anti conformation
required,

and it is subsequently deaminated.

challenge this hypothesis

though

(Crabtree,

11

The results of Crabtree
1979).

Using N-methylformycins

sterically restricted in either the syn or anti conformation as substrates
for human erythrocyte adenosine deaminase,

he demonstrated that this

enzyme is insensitive to the syn anti conformation variable.
suggests

Agarwal

that the increase in Vmax observed for formycin relative to

adenosine may be accounted for by the N7,

N8 diazo bond which would make

C6 more electropositive and therefore favor nucleophilic displacement
(Agarwal,

1975).

As mentioned earlier,

tubercidin was shown by this

author not to be a substrate for adenosine deaminase.
8-azaadenosine are substrates;
imidazole portion of
position,
of

appears

however,

Formycin and

and it is suggested that the

the purine ring of adenine,

in particular the N7

to be an important structural variable in the activity

this enzyme.
The product of

the adenosine deaminase reaction,

be considered a detoxified product of formycin A.

formycin B,

While formycin A was

shown to have an ID50 of 1.0 uM for L1210 leukemia cells,
had an ID50 of 75 uM in this same system (Crabtree,

can

1979).

formycin B
By adding

2'deoxycoformycin the percent growth inhibition of P388 murine leukemia
cells exposed to formycin A was increased from 5% to 71% in the presence
of this adenosine deaminase inhibitor

(Adamson,

1977).

These results

were largely confirmed in viral systems as well where formycin A, but
not formycin B, were shown to inhibit the multiplication of vesicular
stomatitis and vaccinia viruses;

however,

for influenza A virus both

agents were equally effective in inhibiting multiplication
1966;

Giziewicz,

1975).

12

(Takeuchi,

In addition to its cytotoxic effects on P388 and L1210 cells,
formycin has been shown to be cytotoxic to Yoshida rat sarcoma cells
and Ehrlich carcinoma cells,
systems by coformycin,
erythrocyte ADA 1 X 10

cytotoxicity being potentiated in both

another adenosine deaminase inhibitor

-11

M Agarwal,

1977).

(Ki human

Umazawa demonstrated that

daily intraperitoneal injections of formycin into mice with ascitic
Ehrlich ascites carcinoma prolonged the survival of the mice 3 fold,
and that the same increase in survival could be obtained with a

four

fold lower dose of formycin if coformycin were administered concomitantly
(Umezawa,

1967).

This author further demonstrated that formycin B

was not cytotoxic to Ehrlich ascites carcinoma cells and that no
phosphorylated derivitives of

this analog could be detected intracellularly,

unlike formycin A, which was cytotoxic and was
in mono,

di,

and triphosphate forms.

found to exist intracellularly

Further insight into

the metabolism

of formycin was obtained by Sheen who injected mice with formycin and
found 50% of the injected dose in the urine as oxoformycin
the xanthosine analog of formycin B

(Sheen,

1969).

(Fig.

Ill),

It was demonstrated

that the conversion of formycin B to oxoformycin was catalized by hepatic
aldehyde oxidase and that both formycin B and formycin A are competitive
inhibitors of xanthine oxidase.
of the fact that inosine,

These results are surprising in lieu

the structural analog of formycin B,

interact with hepatic aldehyde oxidase,
interact with xanthine oxidase.

does not

nor does adenosine or inosine

Oxoformycin has been shown to be

ineffective as a cytotoxic agent against Yoshida sarcoma cells

13

(Kunimoto,

1968).

In synchronized cultures of HeLa S3 cells,
formycin

(10 ug/ml)

(0.1 ug/ml)

high concentration

inhibited DNA synthesis while low dose formycin

inhibited protein synthesis by 25%

(Kunimoto,

1967).

Kunimoto also demonstrated that the cells were sensitive to inhibition
of cell division by low dose formycin at a stage of early DNA synthesis.
As mentioned above,

DON fibroblasts appeared to be more sensitive

to the cytotoxic effects of tubercidin at the GIS boundry suggesting
perhaps a similarity of cell cycle sensitivity to
In discrepancy with these results

is

these two agents.

the work of Giziewicz who

showed a 95% reduction in both RNA and DNA synthesis of primary rabbit
kidney cells exposed to 200 ug/ml formycin, with an 80-90% reduction
in RNA and DNA synthesis respectively when these cells were exposed to
40 ug/ml formycin (Giziewicz,

1975).

It appears that lower dose formycin

inhibited RNA synthesis less,

and the lack of inhibition of RNA synthesis

observed by Kunimoto may be explained by an insufficiently broad dose
response curve.
As is the case with tubercidin,

the biochemical basis for the

cytotoxicity of formycin has been investigated by numerous authors.
Formycin was shown not to be incorporated into the nucleotide pool of
human erythrocytes, where tubercidin was incorporated and converted to
the triphosphate form (Parks,
in other systems however.

1973).

This result has not been repeated

Mouse leukemia EL4 cells exposed to formycin

were shown to accumulate formycin triphosphate with a dose and time

14

dependent decrease in cellular ATP,
observed with tubercidin
was also demonstrated.

(Zimmerman,

though less of a decrease than was
1978).

The cyclic analog of formycin

Using intraperitoneal injections of formycin into

mice carrying a line of ascitic Ehrlich ascites carcinoma cells lacking
adenosine kinase,

formycin was shown to be ineffective against the kinase

deficient line while inhibiting the parent line by 95% at the same dose
(Caldwell,

1969).

That formycin is indeed a substrate for adenosine kinase was
established using adenosine kinase purified from H.Ep.

it2

cells, where

formycin was found to be phosphorylated at the same rate as adenosine
(Schnebli,

1967).

Further insight into

the biochemistry of formycin

was obtained by Henderson who measured N-formylglycinamide ribonucleotide
levels in Ehrlich ascites
(Henderson,

1967).

tumor cells exposed to azaserine and formycin

In these experiments he demonstrated a 10 fold

decrease in PRPP synthesis
kinase deficient line.

in the parent line as compared to an adenosine

This inhibition of PRPP synthesis, which presumably

occurs at the level of phosphoribose pyrophosphokinase, was also observed
in tubercidin treated cells
de novo purine biosynthesis,

(Henderson,

1965).

In addition to inhibiting

formycin has been shown to decrease

nucleotide synthesis from hypoxanthine and guanine, but not from adenine,
in Ehrlich ascites tumor cells
suggests,

(Henderson,

1967).

As

this author

formycin maybe inhibiting HGPRT directly.

While formycin has not been demonstrated in Vitro or in Vivo
incorporated into DNA,

to be

it has been shown to be a substrate for ribonucleotide
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reductase from Lactobacillus leichmannii where in the absence of dGTP
formycin simply binds to the active site, while in the presence of dGTP
it is reduced (Ward, 1969; Brinkley, 1978).

With respect to CTP reduction,

formycin triphosphate was observed to be ineffective as a positive
allosteric modulator; however, deoxyformycin triphosphate appeared to be
as effective as dATP and deoxytubercidin triphosphate (Suhadolnik, 1968;
Brinkley, 1978).
It appears then that evidence exists that formycin is theoretically
capable, at least in prokaryotes, to enter the deoxyribonucleotide pool;
however, unlike tubercidin it has an absolute requirement for the
binding of dGTP to the allosteric site of ribonucleotide reductase for
this to occur.

Formycin also appears to interact with the allosteric

site of this enzyme differently than tubercidin, in that only deoxyformycin
triphosphate is capable of functioning as an allosteric modulator while
both tubercidin triphosphate and deoxytubercidin triphosphate are effectors.
As can be seen, both formycin and tubercidin can substitute for
adenosine as a substrate in numerous enzyme systems.
universally true however.

This is not

Unlike tubercidin, which was found to substitute

for adenosine in nicotinamide adenine dinucleotide (NAD), formycin has
not been shown to be incorporated into NAD nor was it a substrate for
purified NAD synthase (Ward, 1969).

This author further demonstrated

that formycin triphosphate could substitute for ATP as an energy source
for amino acid esterification to tRNA by aminoacyl-tRNA synthase,
yielding rates of esterification 50%-75% of control depending on the
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amino acid substrate.

On the other hand,

tubercidin triphosphate was

shown to be incapable of serving as an energy source for this enzyme
(Uretsky,

1968).

At the level of cellular metabolism concerned with RNA translation,
both tubercidin triphosphate and formycin triphosphate are utilized by
tRNA CCA pyrophosphorylase,

substituting for adenosine in the 3’

CCA group characteristic of tRNA.
of accepting amino acids,

terminal

The tRNAs thus formed are capable

except for tRNA

Phe

fold decrease in aminoacetylation with Phe.

CCTu, which shows a 20
In addition,

these molecules

appear to vary in their ability to substitute for naturally occurring
tRNA in cell free systems

(Baksht,

1975).

With respect to messenger

function,

both tubercidin and formycin substitute for adenosine with

fidelity;

however,

so.

polyF does not code for polylysine while polyTu does

Studies on the stimulation of binding of aminoacyl tRNA to ribosomes

with formycin or tubercidin containing ribonucleotide polymers has
demonstrated normal to decrease binding for formycin,
for tubercidin (Ikehara,

1965;

1969).

In summary,

but normal binding

the results of these

studies seem to suggest that both tubercidin and formycin can substitute
for adenosine in processes concerned with messenger translation.
is an interesting result in lieu of

This

the data presented earlier that

both compounds inhibited protein synthesis in cytotoxicity studies.
That the inhibition of protein synthesis results from a derangement
at the level of RNA transcription is a possibility; however,
fibroblasts a simultaneous inhibition of DNA, RNA,
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in mouse

and protein synthesis

was observed when these cells were exposed to tubercidin (Acs,

1964).

The rapidity with which tubercidin inhibits protein synthesis would
suggest that tubercidin in some way directly interferes with RNA
translation.
At the level of RNA transcription these analogs appear to behave
differently when used as substrates by RNA polymerase.

While tubercidin

triphosphate is utilized as a substrate by Mengo virus induced RNA
polymerase and QB replicase,

formycin triphosphate is not

That formycin triphosphate is a substrate for Eh

(Kapuler,

1969).

Coli RNA polymerase

has been demonstrated using numerous templates where the rate of
polymerization varied from 23%-34% depending on the template

(Ward,

1969).

Slightly higher rates of polymerization of formycin triphosphate were
observed by Ikehara,
templates

(Ikehara,

47%-68%,
1968).

using Eh

Acs reported that tubercidin triphosphate

could be used in homopolymer formation;
RNA polymerase,

Coli RNA polymerase and various

demonstrated that

however,

Nishimura,

using Eh

the rate of incorporation varied with

the template and that no homopolymer formation could be detected
1964; Nishimura,
synthesis by Eh

1966).

Coli

(Acs,

Formycin triphosphate was not used in homopolymer

Coli RNA polymerase

(Ward,

1969) .

The results of these

studies are significant in that they indicate that with respect to
these sterically different adenosine analogs,

incorporation into RNA is

dependent not only on Watson Crick type base pairing,
conformation of

but on the steric

the neighboring base as well.

In rifampicin challenge experiments DNA dependent RNA polymerase

18

from Azotobactor vinelandii initiated chains with tubercidin triphosphate
at a faster rate than ATP

(Kumar,

1977).

When formycin triphosphate

was used as a substrate for chain initiation;

however,

reaction was 17X larger than the value for ATP.

the tl/2 for this

In phosphodiester bond

formation formycin triphosphate was far more efficient than tubercidin
triphosphate in single step addition while in polymerization it performed
only slightly better.

Darlix also observed a decrease in chain initiation

with normal rates of elongation when formycin triphosphate was used as
a substrate for E.
this,

Coli RNA polymerase

(Darlix,

1971).

In addition to

he observed that formycin prevented the release of newly synthesized

RNA chains

from the transcription complex.

It is interesting that these structurally similar adenosine analogs
would affect different aspects of RNA transcription differently,
one can only speculate as

to

and

the steric variable that restricts formycin

in its ability to initiate RNA chains.

Kumar concluded that only analogs

in the anti conformation are suitable substrates for the initiation of
RNA chains,

thereby explaining why tubercidin with a glycosyl torsion

angle of 73.0 is a better initiator than formycin with an angle of
109.5

(Abola,

1973;

Prusiner,

complicated than this;

however,

aqueous solution tubercidin,
(Evans,

1975).

1973).

The situation appears

to be more

in that Evans demonstrated that in

like formycin,

exists

Whatever the explanation formycin,

in syn anti equilibrium
because of its poor

ability to initiate RNA chains and its retarding effect on RNA chain
release,

can be expected to disrupt RNA transcription to a significant
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extent.

The effects of formycin on RNA processing will be discussed

below.
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8-AZAADENOSINE
9-8-D-ribofuranosyl-8-aza-adenine is

the third adenosine analog

used in this investigation and unlike the other two compounds, which
are naturally occurring nucleoside antibiotics,
chemically synthesized
in 1958,
of this

(Fig.

I).

8-azaadenosine is

Since its first reported synthesis

not much data has been accumulated on the mechanism of action
triazolo adenosine analog

(Davoll,

1958).

It belongs

to

the

general category of 8-azapurine nucleosides such as formycin and
8-azaguanosine,

and like formycin and tubercidin exists in an intermediate

anti syn conformation with a glycosyl
similar to

torsion angle of 103.6,

the angle of formycin (Singh,

1974;

which has an increased glycosyl bond length,

1977).

of the parent compound,

Unlike formycin

the glycosyl bond of

8-azaadenosine is 0.02 A shorter than adenosine.
C8 with nitrogen not only distorts

very

The replacement of

the angles of the imidazole moiety

and provides an additional basic site,

but makes

C6 more electropositive as in the case of formycin.

This variable,

well as

is used to explain

the syn anti conformation of 8-azaadenosine,

as

the higher Km and Vmax when compared to adenosine using purified human
erythrocyte adenosine deaminase
not a substrate,
binding;

however,

(Agarwal,

1975).

Since tubercidin is

these authors concluded that N7 is important in substrate
in 8-azaadenosine N7 is not protonated and therefore

unavailable for hydrogen bonding

(Singh,

1974) .

Taken together this

would imply that N7 may be important in functioning in activities other
than hydrogen bonding.
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Similar results were obtained with adenosine deaminase isolated from
P388 murine leukemia cells,

and in one experiment percent growth inhibition

was increased from 13% to 57% in the presence of dCF
In addition to adenosine deaminase,

(Adamson,

1977).

8-azaadenosine has been shown

to be a substrate for purified adenosine kinase from H.Ep.

#2 cells,

being phosphorylated 1.9X faster than adenosine

1967).

(Schnebli,

3
Using these same cells in culture
converted to mono,

di,

[H

]

8-azaadenosine was found to be

and triphosphate forms

(Allan,

1972).

In

human erythrocytes 8-azaadenosine was found to be incorporated as
monophosphate only

(Parks,

the

1973).

Antitumor activity of 8-azaadenosine has been demonstrated using L1210
and P388 murine leukemia cells where mice carrying these tumors intraperitoneally
had a percent increase in life span of 42% and
treated with 8-azaadenosine

(Montgomery,

1975).

70% respectively when
The mechanism of

this cytotoxicity is difficult to elucidate in that unlike tubercidin
and formycin, which are not metabolized to other potent antineoplastic
agents,

8-azaadenosine is.

8-azaadenine
(Smith,

1957).

As early as 1957 it was recognized that

inhibited the growth of

tobacco mosaic virus and _E.

Coli

Smith suggested that this inhibition was correlated with

the incorporation of 8-azaguanine into RNA by showing that no 8-azaadenine
could be detected in the alkaline hydrolizates of the RNA.

In H.Ep.

#2

cells 8-azaadenosine was found to be 20X more toxic than its aglycone,
implying low conversion of

this substrate by APRT

(Montgomery,

A subline of these cells deficient in adenosine kinase,
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1975).

and another

subline with a combined deficiency in adenosine kinase and APRT, were
both shown to have the same degree of resistance to 8-azaadenosine
implying that this substrate is being metabolized via pathway III
(Fig.

II)

to account for its cytotoxic effects

(Bennett,

1966).

in
Further

elucidation of this mechanism was obtained using a line of cells with
a combined deficiency of adenosine kinase and HGPRT where the degree of
resistance rose to approximately 30X the resistance demonstrated in the
two sublines mentioned previously

(Montgomery,

1975).

Since this

adenosine kinase HGPRT deficient subline was similarly resistant to
8-azainosine,

these authors concluded that the mechanism of cytotoxicity

of 8-azaadenosine resided in its ability to be metabolized to 8-azainosine.
A similar proposal had been made 3 years earlier by Allen who demonstrated
that

3
[ H] 8-azaadenosine was converted by the parent line of H.Ep.

cells to 8-azaAMP,
8-azaIMP

(Allan,

8-azaADP,

1972).

8-azaATP,

#2

as well as small amounts of

When a subline deficient in adenosine kinase

3
and APRT was

incubated with

[ H] 8-azaadenosine,

only a small quantity

of 8-azaIMP could be detected, yet 8-azaadenosine was equally cytotoxic
to both cell lines.

The authors concluded that it was 8-azaIMP that

was the cytotoxic end product of 8-azaadenosine metabolism.

Further

insight into these cytotoxic metabolites was obtained by Bennett who
demonstrated that 8-azainosine increased the life span of mice carrying
intraperitoneal L1210 leukemia cells by 40%-50%,

and that this compound

was equally effective against a line lacking HGPRT and therefore
resistant to 8-azahypoxanthine

(Bennett,
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1973).

Similar results have

also been obtained by Bennett using H.Ep.
confirmed by Montgomery

(Montgomery,

#2 cells in culture and

1975).

These data imply the

existence of an inosine kinase as an alternative route of inosine
metabolism.

When H.Ep.

#2 cells were treated with 8-azainosine the

degree of resistance was observed to increase 20 to 40 fold in a subline
with a combined deficiency in adenosine kinase and HGPRT,
to a subline lacking HGPRT alone

(Montgomery,

1975).

as compared

These authors

concluded that either 8-azainosine is a substrate for adenosine kinase
or that a closely linked inosine kinase was subsequently lost when the
adenosine kinase deficient line was selected for.

Similar results were

obtained by Bennett to explain the cytotoxicity of

7 deazainosine in

these same sublines
that while

[

14

(Bennett,

1966).

C ] 8-azainosine was converted almost exclusively to

8-azaguanine nucleotides by H.Ep.
converted to
1976).
tides

Subsequent studies demonstrated

#2 cells,

[

14

C] 8-azaadenosine was

the nucleotides of adenine and guanine equally

(Bennett,

Similar results are obtained when incorporation into polynucleo¬
(DNA + RNA) were examined.

8-azaadenosine treated cells showed

equal incorporation of adenine and guanine nucleotides,

while 8-azainosine

treated cells showed exclusive incorporation as 8-azaguanine.
H.Ep.

#2 subline lacking adenosine kinase and APRT,

In a

both 8-azaadenosine

and 8-azainosine treated cells demonstrated approximately 90% incorporation
into polynucleotides as 8-azaguanine.

The authors concluded that

8-azaIMP is a substrate for IMP dehydrogenase and GMP synthase,
is not used by the enzymes in the anabolic pathway from IMP
addition to this;

however,

but it

to AMP.

In

one can conclude that the 50% incorporation of
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adenine observed in the parent line treated with 8-azaadenosine is due
to metabolism by adenosine kinase or APRT.

Considering the low toxicity

of 8-azaadenine mentioned earlier it can be concluded that pathway I
in

(Fig.

II), which utilizes adenosine kinase,

pathway III the metabolism of 8-azaadenosine.
H.Ep.
was

shares equally with
When a subline of the

#2 cells resistant to 8-azainosine but sensitive to 8-azaadenosine

treated with 8-azaadenosine,

90% incorporation as adenine was

observed in the polynucleotide fraction.

This

be deficient in adenosine kinase or HGPRT;

line was shown not to

however,

it did show an

approximately 50% reduction in the ability to convert 8-azainosine to
8-azahypoxanthine

(Bennett,

1973).

This data becomes interpretable

if one assumes a concomitant deficiency in inosine kinase,

thereby

leaving only the adenosine kinase pathway accessible for the metabolism
of the 8-azaadenosine,

and no pathway accessible for the metabolism of

8-azainosine in this 8-azainosine deficient line.
In summary,

the cytotoxicity of 8-azainosine may be linked to its

incorporation into DNA and RNA as 8-azaguanine.

While Bennett did not

further define the incorporation into DNA vs RNA,

the majority of

8-azaguanine is most likely incorporated into RNA since negligible
amounts of 8-azaguanine has been noted to be incorporated into DNA in
other systems

(Parks,

1974).

The basis of

the cytotoxicity of

8-azaadenosine may also be linked to its incorporation into DNA and RNA
as observed in the 8-azainosine resistant subline.
however,

In the parent line;

one cannot conclude that cytotoxicity is attributable tc
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8-azaadenosine alone since extensive conversion to 8-azaguanine metabolites
also occurs.

It is interesting in this regard that Adamson observed an

increase in cytotoxicity of 8-azaadenosine to P388 leukemia cells when
these cells were also treated with dCF.

dCF,

by inhibiting adenosine

deaminase, would be expected to block conversion of 8-azaadenosine to
8-azaguanosine.
Like tubercidin and formycin,

8-azaadenosine has been shown to be

a feedback inhibitor of de novo purine biosynthesis in azaserine treated
H.Ep.

#2 cells

(Bennett,

1964).

It is not known;

however,

if this in¬

hibition occurs at the level of amidophosphoribosyl transferase or
phosphoribose pyrophosphokinase,
formycin

(Henderson,

1965;

1967).

In the preceding sections
antitumor agents
reviewed.

as was observed for tubercidin and

tubercidin,

the cellular metabolism of the three
formycin,

and 8-azaadenosine has been

While these compounds are dissimilar only in that they vary

in the imidazole portion of the purine ring of the parent compound
adenosine,

these subtle steric differences are responsible for their

biochemical properties and ultimately their cytotoxic potential.

In

the next section evidence will be presented that these compounds disrupt
RNA processing,

and that their ability to interfere with the methylation

of RNA may be a mechanism by which this occurs.
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-PART TWO-

METHYLATION AND EUCARYOTIC RNA PROCESSING
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In this section the role of methylation in eucaryotic RNA processing
will be briefly reviewed.
HETEROGENEOUS NUCLEAR AND MESSENGER RNA
The process begins with RNA transcription and in eucaryotes three
RNA polymerases have been identified based on their different sensitivities
to the inhibitor a-amanitin,
phalloides.

isolated from the poisonous mushroom Amanita

In animal cells RNA polymerase II is the most sensitive

and it is this polymerase that generates heterogeneous nuclear RNA (hnRNA).
As has been reviewed by Lewin,

the majority of radioactive label incorporated

into hnRNA turns over in the nucleus, implying extensive intranuclear
degradation of this molecule (Lewin, 1980).

Heterogeneous nuclear RNA

has an average length of 8000-10,000 bases and presumably is the precursor
of mRNA, which has an average length of 2000-2100 nucleotides, as suggested
by pulse chase experiments whereby the 3’

terminal poly A and 5' methyl

caps of hnRNA have been shown to be conserved in mRNA.

The function of

these terminal modifications remains obscure but it has been suggested
that they may play some role in message selection from the large pool
of hnRNA precursors.

Only 70% of mRNA from HeLa cells is poly adenylated,

specifically histone mRNA has been shown to lack a poly A tail, arguing
against the necessity of a poly A tail for message transport.

5’ methyl

caps have been shown to be more ubiquitous with only certain viruses
such as polio, encephalomyocarditis,

tobacco necrosis, satellite tobacco

necrosis virus, and yeast killer particle RNA lacking caps (Muthukrishnan,
1978).

Transfer RNA (tRNA) and ribosomal RNA (rRNA) also lack caps
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but are

transported

modification is

As

can be

linked by

This

a 5'-5'

this

1975).

is

type,

the cytoplasm,

required

seen in

structure

are of

not

to

(Fig.

for message

IV),

adenosine.

consists of a

to a

designated as

and while all

only 65%

of

cap

1,

The remaining

where

the

15%

2,

at

the

2'-0-ribose position.

of

third base

V)

where

initiation of

5'

5’

the caps

exists

however,

initiation step

initiation with a

transferase and

is

Next,

ribose of

purine.

that at

caps

end

2'-0-methyl

the second base,

Since

least

36% of

(Furuichi,

1979).

transferase utilizes

these caps

(2'-0;

is

N^)

summarized

to occur after

the

formation may occur

Similar

guanine

to

(Shatkin,

is

(SAM)

1976).

added via

as a methyl

SAM to methylate

analyzed

initiated with a purine,

generated

evidence

7-methylguanine

which for mRNA 64% of bases
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second

of mRNA are designated

that cap

S-adenosylmethionine

caps are

(Cori,

in cytoplasmic polyhedrosis

purine nucleoside,

transcription is

the

1

is additionally methylated

subsequently methylated

7-methyltransferase with

donor.

in

for reovirus and possibly vaccinia virus as well

Following

guanyl

the

of hnRNA

generate dimethyl

the generation of

evidence has been obtained suggesting

as early as

to

the capping reaction is believed

transcription;

7-methyl-guanosine

2’-0-ribose methylated base.

terminal

from the

The putative mechanism for

(Fig.

terminal

the caps on messenger RNA are cap

further methylated at N^

cap

by

cap

pyrophosphate bridge

as

virus

the 5'

that

transport.

Twenty percent of mRNA caps contain adenosine

position which is

in

again demonstrating

this

the

is

a

implies

from internally cleaved precursors.

For those caps having N ,

2'-O-dimethyladenosine,

the base methylation

reaction has been shown to follow the 2'-0-ribose modification
1978).

(Keith,

This enzyme is specific for the cap structure and is not believed

to be involved in the generation of internal N^-methyl adenosine residues.
As appears to be the case for transmethylation reactions in general,
these methyl transferases are inhibited by S-adenosylhomocysteine
the product of SAM coupled transmethylations
As reviewed by Shatkin,

the 5'

(Coward,

this,

mRNA with an unmethylated 5'

1979).

the cap structure

Vaccinia virus

terminal guanosine was shown to have

decreased binding to ribosomes,

(Muthukrishnan,

(Shatkin,

several studies have indicated that

is important in the efficient translation of message.

protein synthesis,

1973).

terminal cap appears to protect RNA

from degradation thereby influencing message turnover
In addition to

(SAH),

as well as poor ability to stimulate

in wheat germ or rabbit reticulocyte lysate systems

1976).

Restoration of ribosome binding capacity and

message function were observed when guanine 7-methyltransferase was
used to remethylate the terminal base.

These authors also demonstrated

that 2'-O-methylation has significantly less influence on ribosome
binding under the in Vitro conditions used.

Similar results were

obtained from studies on the binding of cap modified vesicular stomatitis
virus mRNA,

reovirus mRNA,

and capped synthetic ribopoymers

reticulocyte or wheat germ ribosomes

(Muthukrishnan,

1976).

to rabbit
By using

an RNA (2'-O-methyladenosine-N^)-methyltransferase isolated from HeLa
cells

to generate a dimethyladenosine cap 1 structure on vaccinia virus
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mRNA,

Muthukrishnan showed that this base modification did not increase

the ribosome binding capacity of this mRNA as compared to unmodified
cap 1 containing vaccinia mRNA.

From these studies it can be concluded

that base methylation of the terminal guanosine in the 5'

terminal

caps of RNA has profound effects on ribosome binding, where 2’-0-ribose
methylation and additional base methylations contribute minimally to
this reaction,

at least under the in Vitro conditions examined.

In addition to the methylated nucleosides found in the 5*
caps of both hnRNA and mRNA,

both of these molecules contain internal

m^A and small amounts of m^C,
(Moss,

1977;

Perry,

1975).

ms
trinucleotides GA
C (70%)
HeLa and L cells

(Wei,

except for HeLa histone and globin mRNA

m^A appears
ms
and AA
C

1977;

terminal

to be distributed in the

(30%)

Schibler,

both in hnRNA and mRNA from

1977).

of N^ methyl adenosine in both hnRNA and mRNA,

This similar distribution
combined with the

observation that an increase to 1.0 m^A/1000 bases of mRNA from 0.4
m^A/1000 bases of hnRNA occurs,

is

taken as evidence for the precursor

product relationship of hnRNA to mRNA,
may be involved in this process.
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and that internal methylations

RIBOSOMAL RNA
Another example of conserved internally methylated bases in RNA
maturation is ribosomal RNA processing

(Fig.

VI).

In eucaryotes RNA

polymerase I transcribes a 45s precursor rRNA molecule from clusters
of tandemly repeated ribosomal genes
molecule contains

in the nucleolus.

the sequences of 18s rRNA, which is present in the

40s ribosomal subunit,

as well as

the 5.8s and 28s rRNA sequences which

are found in the 60s ribosomal subunit.
subunit is

methyl groups,

HeLA cell 18s rRNA contains 45

7 of which are base methylations.

methylated groups,

1980).

28s rRNA has 68

5 of which are base methylations,

contains 1 and possibly 2 methyl groups

110-115

The 5s rRNA of the 60s ribosomal

transcribed at a separate locus by RNA polymerase III.

As has been extensively reviewed,

Lewis,

This precursor

(Burdon,

As can be seen the majority,

total methylated nucleotides,

position of the ri'bose.

and 5.8s rRNA

1971; Maden,

1979;

approximately 90% of

are methylated at the 2'

the

hydroxyl

These sugar methylations are believed to occur

rapidly after transcription while the base modifications which include
l-methyladenine,
7
N -methylguanine,

6

N -dimethyladenine,

2
N -dimethylguanine,

and 3-methyluracil,
Using

6

N -methyladenine,

7-methylguanine,

are believed to occur later.

3
[ H ] methionine and

[

32

P]

1-methylguanine,
3-methylcytosine,

5s rRNA is unmethylated.

phosphate to label the RNA of HeLa

cells infected with polio virus, which causes an accumulation of ribosomal
RNA intermediates, Weinberg elucidated the maturation pathway in (Fig. VI)
(Weinberg,

1970).

The 45s precursor is entirely methylated except for
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two adjacent dimethyladenosines,
This precursor gives rise

which later appear in the 18s species.

to a 41s intermediate, which is

to a 32s and 20s fragment.

then cleaved

The 20s species is further processed to 18s

rRNA, while the 32s fragment goes on to 28s and 5.8 s rRNA.
that the ratio of

3
[ H ] methyl groups

to

[

32

P]

By showing

labeled nucleotides

increased during the maturation process, Weinberg was able to demonstrate
that the sequences lost were unmethylated and that the methyl groups
on the original 45s precursor transcript were preserved quantitatively.
As it turns out,

roughly 50% of the 13,000 nucleotides in the original

45s precursor are the unmethylated G-C rich transcribed spacers,

later

to be discarded in the maturation process.
That methylation is

important in this maturation scheme is

suggested

by the results of methionine deprivation experiments in HeLa cells
(Vaughan,

1967).

continue to

HeLa cells deprived of methionine but not valine

transcribe the 45s precursor and process it to the 32s

intermediate,

despite the fact that there are 5X and 3X fewer

2'-0-ribose methylations respectively.

No further processing was

observed in the methionine deprived cells,

and in fact,

were shown to be degraded.

[

treating the cells with

By adding back

14

C]

further intermediates

methionine,

after

actinomycin D to block further transcription,

Vaughan showed that label entered the 45s and 32s rRNA species and could
be detected in ribosomal RNA isolated from the cytoplasm.

He concluded

that methylating enzymes recognize specific sites independent of the
length of the molecule or its stage in maturation.
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It is true that all the methylated sites possess different primary
sequences,

but as Maden points out,

this would require separate methylating

enzymes for each sequence leading to a highly complex scheme
He suggests

(Maden,

1974).

that the functional role of 2'-O-methylation is to protect

against nucleolytic degradation,

and therefore only exposed sequences

would be methylated at the 2'

hydroxyl position by enzymes recognizing

this conformational feature.

Using nuclease S

stranded regions in the nucleic acids,
was

this conformational hypothesis

tested for HeLa cell 18s rRNA (Khan,

that it was

, which hydrolyzes single

1978) .

The results indicated

the four base methylated sites, modified late in maturation,

that were accessible to nuclease S^,

and therefore exposed, with less

than 50% of the sites carrying 2'-0-ribose methyl groups in exposed
positions.

The unexposed methylated sites were presumably modified

early in the maturation process by methylating enzymes
recognize primary sequence,

that apparently

later to be burried by secondary and tertiary

interactions.
As can be seen,

ribosomal RNA maturation is a process

methylated nucleotides.

that conserves

Whether these methylated bases provide specific

recognition sites for the ribonucleases
simply protect the various intermediates
be elucidated.
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involved in this process,

or

from degradation remains

to

TRANSFER RNA
Transfer RNA is the transcription product of RNA polymerase III,
and while being only 73-93 nucleotides in length,
modified nucleic acid in cells
and Smith,

1976).

depicted in

(for reviews see Burdon,

the most highly
1971;

Nau,

1976;

The familiar cloverleaf structure of tRNA is

(Fig.

arm if present,

it is

VII) with the amino acid arm,

and the Tip (pseudouridine)

of the cloverleaf.

the anticodon arm,

C arms representing the leaves

On the average there are 6 to

tides/ tRNA in eucaryotes and unlike rRNA,

extra

7 methylated nucleo¬

ribose methylation accounts

for only 10%-20% of the total methylation.

The species of methylated

bases identified in the tRNA of HeLa and mouse cells include

2

.22

1-methyladenine,

1-methylguanine, N -methylguanine,

7-methylguanine,

5-methylcytosine,

xanthine,

3-methylcytosine,

,

N -dimethylguanine,

and 5-methyluracil with 1-methylhypo-

and 3-methyluracil occurring in minor amounts.

Unlike ribosomal RNA maturation,
in tRNA processing is obscure.
RNA of HeLa cells,

N

the role of methylated nucleotides

Using [

14

C]

uridine to label the small

radioactivity was found to be incorporated into

material migrating between 5s ribosomal and 4s tRNA (Bernhardt,
In actinomycin D block pulse chase experiments,

1969) .

label in this putative

4.5s pre-tRNA was chased into tRNA and further experiments demonstrated
that both pre-tRNA and tRNA incorporated [

14

C]

methylmethionine.

A

possible role for methylation in this maturation process was suggested
by methionine starvation experiments where HeLa cells deprived of
methionine were shown to have a decreased rate of conversion of pre-tRNA
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to tRNA,

as well as a decreased rate of synthesis of

Addition of methionine,
rate of conversion of

but not vlaine,

the precursor.

restored to normal levels the

the precursor tRNA to its mature form.

Bernhardt

also noted that the undermethylated tRNA produced accumulated in the
cytoplasm,

and he concluded that complete methylation is not essential

for tRNA maturation.
Since this early observation,

4.5s pre-tRNA has been observed

in numerous systems including Chinese hamster ovary and Ehrlich ascites
tumor cells

(Choe,

1972).

Analogous

to

the ribosomal RNA precursor,

pre-tRNA from yeast has been shown to contain intervening sequences
which are subsequently removed in the maturation process

(Knapp,

1978).

The location of the maturation events is also a subject of debate;
however,

in experiments with HeLa cells a crude cytoplasmic extract

was shown to convert pre-tRNA to tRNA suggesting that the cytoplasm
is the locus of tRNA processing

(Bernhardt-Mowshowitz,

1970) .

Further insight into the relationship between methylation and
tRNA processing was obtained by Munns

(1975) .

Using human carcinoma

KB cells in labeled methionine pulse chase experiments,

Munns was able

to determine specific methylation events as a function of tRNA
maturation by varying the time of
to the actinomycin D block.

the initiation of the pulse relative

The results indicated that late stage

2
methylations included 2'-0-methylribose,
3-methylcytosine.
5-methylcytosine,

N -methylguanine,

and

Intermediate stage modifications included 1-methyladenine,
and 5-methyluracil while the early methylated nucleotides
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were 1-methylguanine,
was pointed out,

7-methylguanine,

and N

,

N -dimethylguanine.

the late modifications appear restricted to

As

the anticodon

loop and the dihydrouridine arm, while the intermediate stage methylated
nucleotides are found in the TipC loop and arm.
tides appear to reside around the junctions of
Munns concluded that selected regions of
specific

Early methylated nucleo¬
the major arms

(Fig. VII).

tRNA become methylated at

times during the maturation of pre-tRNA.

The enzymes responsible for the generation of
nucleotides,

these methylated

the S-adenosylmethionine tRNA methyltransferases,

a group of "base specific,
that in eucaryotes

species specific,

and organ specific" enzymes

specifically require S-adenosylmethionine

a methyl group donor

(Kerr,

1972).

are

(SAM)

as

They are highly sensitive to

competitive inhibition by the product of the transmethylation reaction,
S-adenosylhomocysteine
to 2 X 10

(SAH),

with Ki values ranging from 6.3 X 10

for various enzymes

of these enzymes

(Nau,

1976) .

is not known with certainty.

—S

M

The cellular location
Cell fractionation

techniques using Krebbs II mouse ascites cells located these enzymes
predominately in the cytoplasm

(Burdon,

1967).

Similar results were

obtained in rat liver cells using in Vivo labeling techniques
(Muranatsu,

1968).

As Burdon points out;

used in the cell fractionation procedures

however,

aqueous media was

and the possibility therefore

exists that the methylating enzymes were extracted from the nuclei during
isolation.

The majority of tRNA methylase activity has been reported

to be associated with nuclei when non-aqueous media was used
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(Kahle,

1971).

While numerous studies have demonstrated that
transferases are a group of tRNA specific,
specific enzymes,

the tRNA methyl-

base and base position

Nau suggests that they can be divided into two

general categories.

The "common methylases" are responsible for the

modification of those bases at sites

that are found to be methylated

on many different tRNA species such as 2'-O-methylguanosine #19,
guanosine #55,

5-methyl uridine #70,

1-methylguanosine #9,
#29,

and in eucaryotes additionally

2

N -methylguanosine #10, N

5-methylcytidine #64 and #65,

7-methyl-

2

,

2

N -dimethylguanosine

and 1-methyladenosine #74.

methylases" would be responsible for the generation of

"Specific

the pattern of

methylation distinctive of each tRNA species.
The biologic role of methylated bases in tRNA remains obscure.
Although the experiments by Bernhardt mentioned previously would seem
to indicate that complete methylation is not critical for tRNA
maturation,
process.

certain key methylations may in fact be important in this

The data obtained by Munns showing that specific methylations

occur in a time ordered sequence of pre-tRNA maturation supports this
point of view.

That methylated nucleotides are important in establishing

and maintaining the unique tertiary structure of tRNA has been proposed,
and in support of

this

is

the observation that the majority of methylated

nucleotides occur in non-base paired regions.

Only N

2

,

2

N -dimethylguanosine

and 5-methylcytosine, which do not prevent G-C hydrogen bonding,
found in helical regions.

To date however,

are

a specific functional role

of methylated nucleotides in tRNA has not been unambiguously assigned.

38

RNA PROCESSING IN DRUG TREATED CELLS
Earlier in this section the maturation of various species of RNA
in eucaryotes was reviewed,

and experimental evidence suggesting that

methylated nucleotides are important in RNA processing was examined.
Tubercidin and formycin have been demonstrated by several authors to
disrupt RNA processing.

Polyacrylamide agarose gel electrophoresis of

total cellular RNA isolated from Novikoff hepatoma cells exposed to
1 ug/ml tubercidin for 2 hours showed approximately 80% inhibition of
3
incorporation of

[

H]

uridine into 32s rRNA,

with greater than 95%

inhibition of incorporation of label into 28s and 18s rRNA as compared
3
to control

(Weiss,

1974).

Incorporation of

f

H]

uridine into 45s and

38s rRNA was the same in control and treated cells.

(Novikoff hepatoma

38s rRNA is similar to the 41s rRNA precursor of HeLa cells.)
mouse tumor cells

L5178Y

treated with 0.05 ug/ml tubericdin for 6 hours were

shown by similar analytic techniques to contain a "high molecular
weight precursor RNA" not isolated from control cells

(Seibert,

1978).

Although this material was not characterized,

it seems possible that it

may be high molecular weight precursor rRNA.

These authors further

demonstrated that tubercidin treated cells contained decreased amounts
of 4s and 5s RNA as compared to untreated cells.
Interference with ribosomal RNA processing has also been
with formycin.

HeLa cells

observed

treated with 25 ug/ml of formycin for 10
3

minutes followed by a 90 minute pulse of [

H] uridine exhibited delayed

processing of 45s rRNA to 32s rRNA (Abelson,
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1973).

With a 30 minute

[ H]

uridine pulse followed by actinomycin D to block transcription and

allow processing of pre-tRNA to the mature 4s form,
demonstrated that cells

these authors also

treated with formycin showed significant inhibition

of cytoplasmic 4s and 5s RNA at a concentration of drug not affecting
the synthesis of hnRNA or 45s ribosomal precursor.

This differential

inhibition of low molecular weight RNA synthesis was also observed in
formycin treated posterior silk glands of the silk worm Bombyx mori
3
(Majima,

1977).

Using pulse chase experiments with

[

H]

uridine,

these

authors made the important observation that the conversion of 4.5s
pre-tRNA to

tRNA was significantly inhibited in formycin treated glands,

while the rate of incorporation of label into pre-tRNA and the disappearance
of pre-tRNA was the same as control.

Glands exposed to

[ ^C]

formycin

were shown to incorporate formycin into total RNA as well as pre-tRNA,
but only negligibly into 4s RNA.

The authors concluded that formycin

containing precursor tRNA was degraded by a scavenger mechanism,

and

in a subsequent study when formycin containing pre-tRNA was incubated
with a crude ribosomal wash from the silk glands,
to accumulate

(Tsutsumi,

1978).

no 4s RNA was observed

4.5s precursor tRNA isolated from

control cells was converted to 4s material by this extract.
In summary,

the above experiments suggest that formycin inhibits

ribosomal as well as tRNA processing from their respective precursors.
Tubercidin likewise inhibits ribosomal RNA maturation,

and although

tubercidin triphosphate was shown by Seibert to inhibit DNA dependent
RNA polymerases I,

II,

and III isolated from mouse liver

(Seibert,

1978),

the studies by Majima and Tsutsumi cast doubt on the hypothesis that
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inhibition of RNA transcription can be used solely to explain the
decreased amounts of cytoplasmic 4s RNA observed in the tubercidin
treated cells.
As mentioned in the previous section, HeLa cells deprived of
methionine were shown to contain undermethylated precursor ribosomal
RNAs that did not complete maturation due to degradation of further
intermediates (Vaughan,

1967).

Similarly, methionine starved HeLa cells

demonstrated a decreased rate of conversion of pre-tRNA to tRNA
(Bernhardt, 1969).

Although Weiss, Majima, and Tsutsumi proposed that

the mechanism of the interference in RNA maturation in tubercidin and
formycin treated cells was due to incorporation of these analogs into
RNA leading to molecules with anomalous properties, when considered
in light of the methionine deprivation experiments another mechanism
becomes plausible whereby these drugs interfere with RNA methylation,
and it is the generation of improperly methylated precursors that
accounts for the inhibition of RNA processing observed.

Evidence does

in fact exist that these analogs, as well as 8-azaadenine, can inhibit
various tRNA methylases in Vitro, albeit at very high concentrations.
Using submethylated tRNA and enzyme extracts from E. Coli,
lumole/ml 8-azaadenine was shown to inhibit tRNA methylation by 10%
(Moore,

1970).

Tubercidin, in concentrations ranging from approximately

300 to 400 ug/ml inhibited tRNA methylation in crude enzyme extracts
of calf liver, E. Coli, and calf spleen by 19%, 24%, and 30% respectively
(Wainfan, 1967).

More specifically,
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tubercidin was shown to inhibit

guanine tRNA methyltransferases from E.

Coli,

and when uracil tRNA

methyltransferase was examined approximately 1 mM tubercidin inhibited
this enzyme by 44%, while at a similar concentration formycin inhibited
this enzyme by only 2%

(Wainfan,

1975).

It can be seen that the evidence that these adenosine analogs can
interfere with RNA methylation is restricted to in Vitro studies,

mostly

with procaryotic tRNA methyltransferases and at very high concentrations
of inhibitor.

The present study was designed to investigate the effects

of tubercidin,

formycin,

and 8-azaadenosine on the synthesis and

methylation of nuclear RNA in L1210 mouse leukemia cells.

Because these

adenosine analogs are dissimilar only in that they vary in the imidazole
portion of

the purine ring of

the parent compound,

it is hoped that

specific structure activity correlates can be deduced.
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-PART THREE-

THE EFFECTS OF TUBERCIDIN,

8-AZAADENOSINE, AND FORMYCIN ON THE

SYNTHESIS AND METHYLATION OF NUCLEAR RNA IN L1210
MOUSE LEUKEMIA CELLS
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ABBREVIATIONS:
nRNA,
dCF,

nuclear RNA;

SDS,

sodium dodecylsulfate;

2'-deoxycoformycin

tetrahydroimidazo

trichloroacetic acid;

[(R)-3-(2-deoxy-B-D-erythropentofuranosyl)-3,6,7,8-

[5,4-d]

3
m C,

3-methylcytidine;

2
m G,

2
N -methylguanosine;

guanosine; m^U,

TCA,

[1,3] diazepin-8-ol], m^A,

5
m C,

1
5-methylcytidine; m G,

2
m^G,

2
N ,

5-methyluridine;

1-methyl-adenosine;

1-methylguanosine;

2
7
N -dimethy1guanosine; m G,
IC^,

7-methyl-

median inhibitory concentration.

MATERIALS AND METHODS:
Materials:

Tubercidin,

8-azaadenosine,

formycin,

and dCF were obtained

from the Drug Synthesis and Chemistry Branch, National Cancer Institute.
3
[5- H-methyl]
and

[U-

14

C]

Thymidine

uridine

Nuclear Corporation,
2
M^G,

7
m G,

Animals:

(20Ci/mmole),

3
L-[methyl- H]

methionine

(80Ci/mmole),

(464 mCi/mmole) were purchased from the New England
Boston,

Massachusetts,

13
5
12
m A, m C, m C, M G, M G,

5
and m U were obtained from P-L Biochemicals, Milwaukee, Wisconsin.
L1210 cells were inoculated,

i.p.,

at an inoculum of 10~* cells/0.1 ml Hanks’

into BALB/c X DBA/2 F^ mice

balanced salt solution.

Cells

were harvested 6 days after inoculation and were further diluted with
incubation medium.
Incubations:

Incubations of L1210 cells were carried out at 37° in a

shaking water bath at 100 r.p.m. and consisted of:
L-methionine-free RPMI 1630 medium,
(80 Ci/mmole)

and 5 uCi

RPMI 1630 medium,

[^c]

5 X 10

uridine

1 X 10^ cells,

luCi
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7

cells,

(1)

200uCi

(464 mC /mmole)
[^C]

uridine

25 ml of

or

3
[ H] methionine
(2)

5 ml of

(464mCi/mmole)

and

5 uCi

3
( H]

thymidine

(20 Ci/mmole).

Cells were preincubated with luM

dCF for 15 minutes before further incubation for 30 minutes with either
tubercidin,

8-azaadenosine,

or formycin.

Total RNA and DNA Synthesis:

The period of labeling was 1 hour.

Incorporation of

[

14

C]

uridine and

3
[ H]

thymidine into total RNA and DNA respectively was measured by cooling
the incubation flasks on ice for 15 minutes and adding ice-cold TCA to a
final concentration of 10%

(w/v).

Precipitates were collected on glass

fiber filter discs, washed 3X with 5% TCA and 2X with 95% ethanol.

Discs

were dried and counted in 10 ml Aquasol in a Searle Mark III liquid
scintillation system.
RNA Extraction:

After incubation,

cells were centrifuged at 400g for 20

minutes at 4° C, washed once with cold RPMI 1630 medium,
at 400 g for an additional 10 minutes at 4° C.

and recentrifuged

Nuclei were prepared from

the cell pellet by resuspension in 10 ml of lOmM magnesium acetate swelling
medium (pH 5.1)

for 15 minutes at 4° C.

This swelling medium was

previously found to markedly inhibit the activity of intracellular RNase,
thereby minimizing the hydrolysis of nRNA before extraction.

The samples

were then adjusted to room temperature by stirring for 10 minutes at room
temperature,

followed by the addition of 0.15 ml of Triton X-100 for an addi¬

tional 5 minutes.

Nuclei were collected by centrifugation at

10 minutes at 4° C and resuspended in 5 ml of 0.34 M sucrose,

2000 g for
5mM magnesium

chloride which was layered on a cushion of 5 ml of 0.88 M sucrose,
mM magnesium chloride,

5

and centrifuged at 2000g for 10 minutes at 4°C.

nRNA was extracted from the pelleted nuclei by vortexing vigorously for
2 minutes with 3 ml of 0.1% SDS:

0.14M NaCl:
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0.025M sodium acetate

(pH 5.1)

and 3 ml of phenol mixture

(phenol-m-cresol-water

containing 0.1% 8-hydroxyquinoline.

(7:2:2), v/v)

The emulsion was clarified by

centrifugation at 12,000g for 10 minutes,
was removed and precipitated with 3 vol.

and the upper aqueous phase
of 2% potassium acetate in 95%

ethanol at -20°C overnight.
DEAE Sephadex-Urea Chromatography:

precipitated RNA was collected by

centrifugation at 10,000g for 20 minutes at -10° C.

The precipitate

was washed with cold 95% ethanol and recentrifuged at 10,000g for
10 minutes at -10° C.

The pelleted RNA was hydrolyzed at 37° C

overnight in 0.5 ml of 0.3 N potassium hydroxide.

Phenolphthalein was

added as an indicator and the pH adjusted with perchloric acid till
slightly basic.

The samples were allowed to stand on ice for 20

minutes followed by centrifugation at 2000g for 10 minutes at 4°
to remove the potassium perchlorate precipitate.
was diluted to 10 ml in buffer:

20mM Tris HCl

C

The supernatant

(pH 7.6),

7 M urea

and absorbed onto a 0.9 cm X 15 cm column of DEAE sephadex equilibrated
in buffer.

The column was washed with 10 ml of buffer and eluted with

a 200 ml linear gradient of 0.1 M NaCl

to 0.7 M NaCl

were collected, mixed with 15 ml of Hydroflour,

2 ml fractions

and counted in a Searle

Mark III liquid scintillation spectrometer.
Electrophoresis:

nRNA was resolved by electrophoresis

polyacrylamide gels
0.32%

(w/v)

(0.4 X 7 cm)

diallyltartardiamide,

ammonium persulfate,

0.04%

(v/v)

containing:
6 M urea,
N,
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N,

in cylindrical

8%

(w/v)

acrylamide,

0.1%

(w/v)

SDS,

0.2%

(w/v)

N', N'-tetramethylenediamine,

0.4 M Tris-acetic acid
M EDTA.

(pH 7.2),

0.02 M sodium acetate,

RNA samples containing one

unit were mixed with sample

buffer to give a final concentration of:
(pH 7.2),
and 20%

0.02 M sodium acetate,

(w/v)

at 4° C.

sucrose

0.04 M Tris-acetic acid

0.002 M EDTA,

(RNase-free).

and 0.002

0.02% bromphenol blue

Gels were electrophoresed at 4mA/gel

Gels were sectioned into 2 mm slices,

dissolved in 2%

(w/v)

periodic acid at 37° C for 15 minutes, mixed with 10 ml Aquasol,

and

counted in a Searle Mark II liquid scintillation spectrometer.
Thin-Layer Chromatography:
electrophoresis.

4S RNA was

isolated by polyacrylamide gel

4S RNA was sliced from the appropriate section of the

gel and sectioned into

2 mm slices.

RNA was extracted from four gel

slices with 1 ml of RNA extraction buffer
0.025 M sodium acetate,

pH 5.1)

temperature for one hour.

(0.1% SDS:

by continuous vortexing at room

The gel was removed by centrifugation at

16,000g for 2 minutes in an Eppendorf centrifuge,
precipitated at -20° C for 2 hours.

and the RNA was

Enzymatic digestion was carried

out for 18 hours at 37° C in 20 ul of 0.05 M Tris-HCl
MgCl^ containing:
phatase

6 ug RNase A,

(1000 units/mg)

0.014 M NaCl:

(pH 8.0):

5mM

5 ug calf intestine alkaline phos¬

and 10 ug snake venom phosphodiesterase.

Samples were freeze dried and reconstituted with 20 ul of a standard
mixture containing the eight methylated nucleosides at a concentration
of 0.4 mg/ml.

An aliquot of 5 ul was spotted on 0.25 mm silica gel

plates containing fluorescent indicator
New York),

(EM Laboratories,

Elmsford,

and the eight methylated nucleosides were separated by two-

dimensional thin-layer chromatography with acetonitrile-concentrated
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NH^OH
(10:1,

(4:1,
v/v)

v/v)

for the first dimension and acetonitrile-2 N HCOOH

for the second dimension.

the area corresponding to
of Aquasol,

Silica gel was recovered from

the appropriate standard,

mixed with 10 ml

and counted in a Searle Mark III liquid scintillation

spectrometer.
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RESULTS
Initial experiments were designed to assess the effects of tubercidin,
8-azaadenosine,

and formycin on total RNA and DNA synthesis in the presence

and absence of 1 X 10 Si dCF

(Fig.

VIII).

It is apparent that inhibition

of both RNA and DNA synthesis by 8-azaadenosine and formycin are
potentiated in the presence of the adenosine deaminase inhibitor, while
tubercidin inhibited the synthesis of both of

these macromolecules

the same extent irrespective of pretreatment with 1 uM dCF.
doses of
as

to

Lower

tubercidin inhibited DNA synthesis more than RNA synthesis but

the dose was increased the synthesis of both RNA and DNA became

inhibited to the same degree with an IC^ °f approximately 7 X 10
for both macromolecules.

In the presence of dCF,

1 X 10 ^ and 1 X 10

8-azaadenosine inhibited RNA synthesis by 40% but DNA synthesis by only
10%-15%.

Similarly,

1 X 10

-4

M and 1 X 10

-3

M formycin plus dCF inhibited

RNA synthesis by 40%-80% and DNA synthesis by 30%-40%.
dCF, which was used throughout all the experiments,

1 X 10

did not affect RNA

or DNA synthesis.
To examine the effects of these analogs on RNA synthesis and
methylation,
[

14

C]

3
nRNA was double-labeled with L-[ methyl- H]

uridine,

Sephadex

methionine and

and the alkaline hydrolysates chromatographed on DEAE

(Table 1,

Fig.

methylation relative to

IX).
[

14

C]

All three drugs preferentially inhibited
uridine incorporation only in the

mononucleotide fraction (-2 charge)

representing methylated bases.

This

differential inhibition was not evident in either the dinucleotide fraction
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(-3 charge)
fraction

representing 2'-O-methylation,

(-5 charge)

representing 5’

or in the tetranucleotide

cap structures.

Alkaline

hydrolysates from cells treated with dCF plus formycin demonstrated an
3
additional peak containing 1.7% of the total incorporated
activity which eluted before the mononucleotide
panel D).

[

H]

radio¬

(-2) peak (Fig.

This material was not characterized further.

IX

1 X 10

dCF did not affect the synthesis or methylation of nRNA.
Because of

the observation that tubercidin,

dCF plus 8-azaadenosine,

and dCF plus formycin preferentially inhibited base methylation,

nRNA

was next fractionated using electrophoresis in denaturing polyacrylamide
gels to determine if these effects were largely restricted to 4S nRNA
which is rich in methylated bases
tubercidin,

(Table 2,

Fig. X).

At 4 X 10

methylation was preferentially inhibited relative to

uridine incorporation for both >18S nRNA and 4S nRNA.
8-azaadenosine plus dCF; however,
for only >18S nRNA,

while 1 X 10

-4

these drugs 10 fold,

14

C]

1 X 10 \

preferentially inhibited methylation
formycin plus dCF preferentially

inhibited the methylation of only 4S nRNA.
of

[

By increasing the concentration

the preferential inhibition of methylation

relative to synthesis was no longer observed, with the exception of the
effect dCF plus 8-azaadenosine on >18S nRNA.
[

14

C]

uridine incorporation data,

By considering only the

it is apparent that 4 X 10

-6

M

tubercidin inhibited the synthesis of >18S nRNA and 4S nRNA to
approximately the same extent,

but when the dose was increased to 4 X 10

the synthesis of 4S nRNA was more severely inhibited
plus 1 X 10

-5

M 8-azaadenosine appeared to inhibit
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[

14

(Table 2).
C]

uridine

dCF

incorporation into 4S nRNA more than >18S

nRNA,

but at a 10 fold

higher dose no differential inhibition of the synthesis of
classes of nRNA could be detected.
formycin;

however,

these two

In the case of dCF plus 1 X 10

-4

M

4S nRNA synthesis was inhibited to a greater degree

than >18S nRNA synthesis,

and this differential inhibition of low

molecular weight nRNA was also observed at the 10 fold higher dose.
To determine if these drugs inhibited the same,

or a different

spectrum of base methylating enzymes, methylated nucleosides isolated
from 4S nRNA were resolved by two-dimensional thin-layer chromatography
(Table 3).

It appears that the degree of methylation of m^A was

_6
relatively unaffected by any of these drugs.

4 X 10

M tubercidin

appeared to markedly affect the methylation of most of the other
5
5
with the possible exception of m C and m U.

nucleosides rather broadly,

dCF plus 1 X 10 \ 8-azaadenosine seemed to have a more specific effect,
3
inhibiting the methylation of m C more severely than the other nucleosides.
dCF plus 1 X 10

-4

M formycin;

3
the methylation of m C,

however,

appeared not to markedly inhibit

as did tubercidin and dCF plus 8-azaadenosine,

but did severely inhibit the methylation of m^C, which the other two
drugs appeared not to do.
dCF plus 1 X 10

-4

Other than this apparently specific effect,

M formycin markedly inhibited the methylation of most

1
3
of the nucleosides with the exception of m A and m C mentioned earlier,
2
5
and possibly m G and m U as well.
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DISCUSSION
In examining the affects of tubercidin,

8-azaadenosine,

and formycin

on total RNA and DNA synthesis as measured by incorporation of labeled
uridine and thymidine respectively into TCA precipitable material,

it

was determined that the effects of both formycin and 8-azaadenosine
were potentiated by dCF, while tubercidin was insensitive to the action
of this adenosine deaminase inhibitor.

These results are consistent

with the high level of adenosine deaminase in L1210 cells and are in
agreement with the data obtained by Adamson who demonstrated that
8-azaadenosine and formycin,

but not tubercidin,

of P388 mouse leukemia cells

to a greater extent in the presence of

dCF

(Lepage,

1969;

Adamson,

1977).

inhibited the growth

Also in support of this data are

the numerous in Vitro studies demonstrating that tubercidin is not a
substrate for purified adenosine deaminase,
formycin are.

while 8-azaadenosine and

As discussed under Cellular Metabolism,

8-azaadenosine

is extensively metabolized to 8-azaguanine nucleotides by what appears
to be pathway III in (Fig.
and it can be assumed,

II).

dCF,

however, would block pathway III

in the absence of unknown purine pathways,

that

the effects of 8-azaadenosine on dCF pretreated cells are in fact due
to 8-azaadenosine,

and not some other metabolic product.

From the gel electrophoresis study it appears

that lower dose

tubercidin inhibited the synthesis of >18S nRNA and 4S nRNA to
extent,

the same

while at the higher dose 4S nRNA was more specifically inhibited.

The "high molecular precursor RNA" reported by Seibert to be isolated
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only from tubercldin treated, but not from control, L5178y mouse tumor
cells was not observed In this study (Fig. X panel B)

(Seibert, 1975).
■k

Specific inhibition of 4S RNA synthesis was also observed with formycin,
both at high and low doses, while 8-azaadenosine probably did not
specifically inhibit the synthesis of one species of nRNA vs the other
since no consistent dose effect relationship could be ascertained.
The observation that formycin specifically inhibits the synthesis
of low molecular weight RNA has also been made in HeLa cells and in the
posterior silk gland of the silk worm Bombyx mori (Abelson, 1973;
Majima, 1977).

The results obtained by Majima and Tsutsumi (1978)

suggesting that in formycin treated silk glands precursor tRNA did not
process to the mature 4S form, and that it was degraded by a scavenger
mechanism, forces one to interpret with caution RNA synthesis data
based on

14
f C ] uridine incorporation into TCA precipitable material.

Although no data exists that tubercidin or 8-azaadenosine treated cells
produce unstable RNA,

it is not unreasonable to assume in absence of

data to the contrary,

that these drugs may also cause the synthesis

of unstable RNA, later to be degraded by some scavenger pathway.
Weiss, Majima, and Tsutusmi proposed that the mechanism of inter¬
ference in RNA processing in tubercidin and formycin treated cells was
due to incorporation of these analogs into RNA leading to molecules

*In this section, when results of this study are referred to,
formycin = formycin + dCF data, and 8-azaadenosine = 8-azaadenosine + dCF
data.
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with anomalous properties.

In this study tubercidin,

formycin,

and

8-azaadenosine all were shown to preferentially inhibit base methylation
relative to synthesis of nuclear RNA,

supporting the hypothesis

that

defective methylation may be the common denominator for the interference
in RNA processing observed in drug treated cells.

It is interesting to

note in this regard that formycin, which was reported to interfere with
the processing of pre-tRNA to tRNA (Majima,

1977),

the methylation of 4S nRNA at a dose of 1 X 10

-4

If degradation of unstable RNA is occurring,
it is undermethylated precursors
ratio of

[

3

H methyl]

(Table 2).
and especially if

that are being degraded,

methionine to

artificially increased,

M

preferentially inhibited

[

14

C]

then the

uridine incorporation will be

and one would interpret this as there being

a less specific effect on the inhibition of methylation vs synthesis.
For instance,
Fig.

IX,

the base methylation data

(-2 charge)

in (Table 1;

panels B,C,D) would demonstrate an even more pronounced specific

inhibition of methylation compared to synthesis in the absence of
conjectural degradative pathways.

these

Since 2'-0-ribose methylation is

believed to protect RNA from nucleolytic degradation,

it is possible

that in the drug treated cells the lack of a specific inhibition of
ribose methylation relative to
dinucleotide fraction

[

14

C]

uridine incorporation in the

(-3 charge) may be an artifact due to degradation

of molecules lacking appropriate 2*-0-ribose methylations.
As mentioned previously,

the lower dose of formycin used preferentially

inhibited the methylation of 4S nRNA relative to > 18S nRNA (Table 2).
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8-azaadenosine had the opposite effect,

specifically inhibiting the

methylation of > 18S nRNA, while tubercidin appeared to inhibit the
methylation of both of these species

to the same extent.

This specificity

of inhibition was largely abolished at the higher concentrations of
the drugs used,

probably because of the severe inhibition of RNA synthesis

at the higher dose,

except for 8-azaadenosine treated cells which

maintained a comparable rate of RNA synthesis at the two concentrations
investigated.
Examination of the methylated nucleosides contained in 4S nRNA
suggested that each drug inhibited its own spectrum of RNA methylating
enzymes

(Table 3).

While the 4S nRNA species isolated from the 8%

denaturing polyacrylamide gels was not characterized further,

it most

probably represents precursor tRNA as well as some small nuclear RNA
species and possibly mature tRNA,

since these gels are not capable

of resolving 4S from 4.5S RNA species.

It is apparent that neither

tubercidin,

8-azaadenosine,

degree.

the assumption is made that L1210 cells process precursor

If

nor formycin inhibited m"*~A to any significant

tRNA to tRNA by the same scheme of

time and position ordered base

methylations worked out for KB cells by Munns
the data in

(Table 3)

to

(1975),

then by comparing

this scheme certain generalizations with

respect to inhibition of groups of enzymes may become apparent.

Both

tubercidin and formycin more severely inhibited the methylation of those
nucleosides clustered around the junctions of the major arms,
which is found only in the extra arm,
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and m^G

those methylations occurring early

in pre-tRNA processing

(Fig.

VII).

These methylated bases are also

related by the fact they are all guanine nucleosides.
this effect,

In addition to

tubercidin also inhibited to a greater extent those

bases clustered in the anticodon loop and dihydrouridine arm,
stage methylations.

Formycin showed relative sparing of

the late

this region,

but demonstrated severe inhibition of m^C, which neither tubercidin
nor 8-azaadenosine appeared to do.

It is interesting to note that

8-azaadenosine showed the most specific effect on the inhibition of
3
base methylation, where m C was inhibited the most of the 8 methylated
nucleosides examined.
With respect to structure activity correlation,
(Table 3)

the drugs in

are arranged in order of increasing glycosyl bond length and

increasing glycosyl torsion angle from top to bottom.
glycosyl bond length and torsion angle is

Increasing the

theoretically associated with

increasing freedom of rotation around the glycosyl bond,

allowing the

compound to assume either the syn or anti conformation.

When the data

are examined in this way no pattern of inhibition of methylated
nucleosides becomes apparent.

Formycin,

studied with its C-C glycosyl bond,
5
3
of m C more and m C less

unique amongst the compounds

seemed to inhibit the methylation

than the other analogs.

only triazolo nucleoside investigated,

8-azaadenosine,

the

3
seemed to affect m C more

specifically than the other drugs.
When the synthesis and methylation of > 18S nRNA and 4S nRNA are
examined with respect to the structural variables of glycosyl bond
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length and torsion angle,

again no pattern of inhibition of synthesis

or methylation becomes apparent.

8-azaadenosine did not show specificity

in inhibition of nRNA synthesis as did formycin and higher dose
tubercidin,

but did show specificity in the ability to inhibit the

methylation of >18S nRNA.
Several studies have shown that tubercidin,

8-azaadenosine,

and

formycin are all extensively metabolized in cells and the question
arises as

to whether the inhibition of methylation of nRNA observed in

this study is due to the direct effects of these drugs,
metabolic product.
in this study,

While this question was not addressed experimentally

examination of

(Fig.

XI), which summarizes

cellular metabolism of S-adenosylmethionine
(SAH),

(SAM)

brings several speculations to mind.

alluded to earlier,

the eucaryotic

and S-adenosylhomocysteine

The first possibility,

is that these drugs directly inhibit the SAM dependent

RNA methyltransferases.

Alternatively,

they or their nucleotide derivatives

could inhibit methionine adenosyltransferase,
intracellular concentration of SAM,

and by lowering the

inhibit more severely those methyl-

transferases with a higher Km for SAM.
of

or to some

If the triphosphate derivatives

these drugs are suitable substrates for methionine adenosyltransferase,

then the formation of an analog containing counterpart of SAM may lead
to a molecule capable of inhibiting the methyltransferase enzyme.
Lastly,

by progressing further along the pathway shown in

homocysteinyl derivative of the analog would be formed,
that it is the homocysteinyl derivative of tubercidin,

(Fig.

XI),

the

and it is possible
8-azaadenosine,

and formycin that is responsible for inhibiting the RNA methyltransferases.
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Using a crude preparation of tRNA methyltransferases isolated from
rat liver,

SAH and S-tubercidinylhomocysteine

almost identicle Ki values,

(STH) were shown to have

25 uM and 20 uM respectively

(Coward,

1974).

When more purified methyltransferases from the same source were examined,
8-azaadenosylhomocysteine was shown to be a better inhibitor of
adenine-1 methyltransferase than STH or SAH, but STH and SAH were the

2

superior inhibitors of N -guanine-I and guanine-1 methyltransferase
respectively

(Leboy,

1978).

In another methyltransferase reaction,

STH inhibited Newcastle Disease Virion mRNA (guanine-7-)-Methyltransferase
with a Ki 36% of SAH, while 8-azaadenosylhomocysteine inhibited this
methyltransferase with a Ki 8.5X larger than SAH

(Pugh,

1977).

Several authors have demonstrated that STH is capable of inhibiting
in Vivo RNA methylation.

STH was shown to inhibit base methylation,

well as 2’-0-ribose methylation,

as

as determined by the appearance of

cap 0 and decreased amounts of cap 2 structures in cytoplasmic poly A
containing RNA isolated from treated Novikoff hepatoma cells
1977).

(Kaehler,

Phytohemagglutinin-stimulated rat lymphocytes exposed

demonstrated a 49% inhibition of methylation of tRNA,

to STH

and when the

methylated nucleosides of tRNA isolated from STH treated Novikoff
2
7
hepatoma cells were examined, m^G and m G showed 90% and 83% inhibition
of methylation respectively, while m^A and m^U were uninhibited
1975;

Coward,

1979).

(Chang,

This is an interesting result when compared to

the data obtained in this study where tubercidin inhibited the methylation
2
7
15
of m^G and m G to a greater extent than m A and m U.
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The question of whether tubercidin of S-tubercidinylhomocysteine is
responsible for inhibiting methylation is most directly addressed by
the research of Kaehler who studied the methylation of poly A containing
RNA isolated from Novikoff hepatoma cells
adenosylhomocysteine,
1979).

tubercidin,

treated with either homocysteine,

or tubercidinylhomocysteine

By examining the ratio of the incorporation of

methionine to

[

14

C]

uridine,

3
[ H-methyl]

Kaehler showed that STH had specifically

inhibited methylation relative to
tubercidin did not.

(Kaehler,

[

In this study,

14

C]

uridine incorporation, while

4 X 10

tubercidin was shown to

abolish the preferential inhibition of methylation of > 18S nRNA observed
at 4 X 10 Si,

and it is possible that the lack of specific inhibition

of methylation observed by Kaehler using tubercidin at a dose of
10

-4

M was due to too high a dose of tubercidin.

methylation,

In reference to 2’-0-ribose

Kaehler further demonstrated that cap 0 structures were

isolated only from STH,

but not tubercidin treated cells;

tubercidin treated cells demonstrated 13X and 20X more cap
than control or STH treated cells respectively.

however,
2 structures

In this study tubercidin

appeared not to specifically inhibit 2’-0-ribose methylation
-3 charge;

2.5 X

Fig.

IX,

panel B),

(Table 1,

but as discussed earlier possible degradation

of RNA lacking appropriate 2'-0-ribose methylation may have obscured any
specificity in the inhibition of 2'-0-ribose methylation by tubercidin.
The DEAE sephadex-urea chromatography technique used in this study was of
insufficient resolving power to separate the different species of 5'
caps and so no conclusions can be made in reference to

them.

In summary, other studies have shown that tubercidin and formycin
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interfere with RNA processing and it has been suggested that incorporation
of

these drugs into RNA is responsible for this effect.

investigation tubercidin and formycin,

In this

as well as 8-azaadenosine, were

shown to inhibit the methylation of nuclear RNA in L1210 mouse leukemia
cells by a mechanism that remains unknown at present.

This inhibition

of methylation of nRNA suggests an alternative hypothesis whereby the
production of defectively methylated RNA is responsible for the reported
interference in RNA maturation by these drugs.
to investigate other agents

It would be interesting

that interfere with RNA processing to see

if they too have any effect on the methylation of RNA.
tubercidin,

8-azaadenosine,

Alternatively

and formycin, because of their ability to

inhibit RNA methylation, may prove useful in probing the role of
methylation in the fascinating process of RNA maturation.
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-PART FOUR-

FIGURES AND TABLES
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STRUCTURE OF
TUBERCIDIN, FORMYCIN, AND 8-AZAADENOSINE

HO

OH

HO

Syn

OH
Anti

TUBERCIDIN

FORMYCIN

8-AZAADENOSINE

Figure I

of

Dashed bonds in tubercidin illustrate angles used in the calculation
the glycosyl torsion angle.
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Eucaryotic Purine Metabolism

Xanthine
,,oxidase
URIC

ACID

Figure II
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METABOLISM

OF

FORMYCIN

Ribose
Adenosine
deaminase

Ribose
Hepatic
Aldehyde
(r oxidase

Ribose

Figure III
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A

Structure of the 5'Terminal Cap

NH

*■ w

0= P- o-ch2

x

O’ OH

Figure IV
Illustrated is the structure of

7Me

2' OMe
G(5')ppp(5')A^ ^ pApX,

a Cap 1 structure.

6
Filled squares are methyl groups.
methyl group forming cap 2.
(Lewin,

Arrow indicates position of additional
7Me
Cap 0 would have only terminal
G(5')ppp(5’)X,

1980).

65

:a.r.

Synthesis of the 5'Terminal Cap
Gppp + (ppApNp-or pppApNp-)
Guanyly I
transferase

GpppApNp SAM-

7- Methyltransferase

SAH

7 Me

GpppApNp

SAM
SAH
7Me

2'-0- Methyltransferase
[ 2'0Me

GpppA

pNp-

SAM
2'-0- Methyladenosine
g

SAH
7Me

N methyltransferase
' r

GpppA

2'OMe
N Me PNP-

Figure V
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Illustration of Eucaryotic RNA Processing

Figure VI
Ribosomal RNA processing sequence as determined in HeLa cells
(Lewin, 1980).
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Structure of Transfer RNA

Amino
Acid
Arm
A
C
C

T¥C
Arm

DHU
Arm

A
o

early
intermediate

□

late

Figure VII
y

= pseudouridine,

DHU = dihydrouridine.

Early,

intermediate,

and

late refer to stages of base methylation in tRNA maturation as determined
by Munns (1975).
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DOSE-RESPONSE OF RNA AND DNA SYNTHESIS BY TUBERCIDIN,

8-AZAADENOSINE

AND FORMYCIN

O
cc
O

u

10 -5

10 -6

10'

10

-3

CONCENTRATION (M)

Figure VIII
L1210 cells
(0,0)

(1 X 10^ cells/flask) were preincubated with

1 X 10~6M dCF,

8-azaadenosine

(B)

or without

and incubated for 30 minutes with tubercidin

or formycin (C).

(A),

Cells were then double-labeled for 1

( , )

hour with [^C] uridine 0 9
and [^H] thymidine
and TCA-precipitable
radioactivity was determined as described under Materials and Methods.
Each
value is

the mean of two to three determinations.
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DEAE SEPHADEX-UREA CHROMATOGRAPHY OF ALKALINE HYDROLYSATES OF nRNA

o
<
cr

Figure IX
L1210 cells

(5 X 107 cells/flask) were preincubated for 15 minutes

with (C and D) or without (A and B) 1 X 10_6M dCF and incubated for
30 minutes with 4 X 10“6M tubercidin (B) , IX 10-;)M 8-azaadenosine (C) ,
or 1 X 10“^M formycin (D).

Cells were then double-labeled for 1 hour

with 200 uCi L-[methyl-3H] methionine and 5 uCi I14C] uridine.
DEAE
sephadex-urea chromatography as described under Materials and Methods.
The -2, -3, -4, and -5 markers represent the net charge of mono, di,
tri, and tetranucleotides, respectively, eluted with the NaCl gradient.
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Table 1.

DEAE Sephadex-urea chromatography of alkaline hydrolysates of nRNA
from L1210 cells treated with tubercidin, 8-azaadenosine and formycin*

RNA fraction (103 d.p.m.)

-2

Treatment

■Hi
268 + 28

Control

-3

-5

14c

Hi

14c

110 + 6

186 + 19

4.15 + 0.91

14c

3h
20.6 + 1.7

0.55 + 0.16

X of control
Tubercidin

59

99

77

53

47

0

9

16

14

2

8

0

M

45

62

57

42

29

26

1x10"4M

50

61

61

43

35

0

1x10“4M

28

73

59

21

26

0

1x10“3M

14

38

32

10

14

0

4x10"6M
4x10'5M

dCF+8-Azzadenosine

1x10

-5

dCF+Formycin

♦Values for pooled controls (with and without dCF) represent the means + S.E. of four determinations.
Values for incubations with the lower concentration of each drug represent the mean ot two determinations, and
at the higher concentration of each drug a single determination.
L1210 cells were incubated with tubercidin,
dCF + 8-azaadenosine, or dCF + formycin followed by labeling with L-[roethyl-^H] methionine and [
C] uridine
as described under Materials and Methods.
The fractions -2, -3, and -5 denote the net charge of mono, di,
and tetranucleotides of alkaline hydrolysates of nRNA eluted by DEAE Sephadex chromatography depicted in
(Fig. IX).
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POLYACRYLAMIDE GEL ELECTROPHORESIS OF nRNA

Figure X
L1210 cells

(5 X 10^ cells/flask) were treated as described in

(Fig.

IX)

and electrophoresed in denaturing 8% polyacrylamide-urea gels as described
under Materials and Methods.
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Table 2.

Effects of tubercidln, 8-azaadenoslne and formycin on the
methylation and synthesis of nRNA from L1210 cells*

RNA fraction (2 of control)

4SRNA

>18S

Total
14,

14

14
C

C

Treatment

Tubercidin
4x10~6M

57+2

85+2

50 + 5

75 + 8

43+3

61+8

4x10_5M

16+3

8+2

15+3

15+3

14 + 4

2 + 1

dCF+8-Azaadenosine
1x10_5M

47+2

62+2

45+4

70+9

38 + 6

40 + 10

1x10~AM

42+3

63+4

32+3

58+10

30+8

40+12

33 + 2

55 + 2

52+7

57+4

25+1

41+4

32+8

14+3

12+2

dCF+Fonnycin
1x10_AM
1x10_3M

27 + 1

35 + 1

22+6

♦Values represent the means + S.E. of three to six determinations.
L1210 cells were incubated with
tubercidin, dCF + 8-azaadenosine, or dCF + formycin followed by labeling with L-[methyl- H] methionine and
[14C] uridine as described under Materials and Methods.
Nuclear RNA was isolated and electrophoresed in
82 polyacrylamide-urea gels as depicted in (Fig. X).
Radioactivity in > 18S and 4S nRNA was calculated
from the radioactivity present at the top of the gel and the 4S region, respectively.
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Table 3.

Effects of tubercidln, 8-azaadenoslne and formycin on the
composition of methylated nucleosides in 4S nRNA from L1210 cells*

Methylated nucleoside (d.p.m.)

Treatment
Control

m^G

m^C

m3C

m2G

m2G

m^G

m5U

1.
m A

3230

2220

630

4590

4290

2520

3430

300

/ of control

Tubercidln
4x10-6M

20

54

27

32

36

28

41

88

47

42

27

55

50

42

53

93

25

9

40

30

17

19

31

83

dCF+8-Azaadenosine
1x10_5M

dCF+Formycin
1x10_4M

*Each value is the mean of two determinations.
Thin-layer chromatography and determination of
radioactivity as described under Materials and Methods.
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Eucaryotic Metabolism of S-Adenosylmethionine
and S-Adenosylhomocysteine

Methyl —v.
acceptor
Methylated^'
acceptor
|S-ADENOSYLHOMOCYSTEINE |

0

I amp!

I ADENOSINE
Adenosine kinase I
-or--I ADA
Purine
I NOSINE
Nucleoside
l
phosphorylase
I
APfijT

Adenosylhomocysteinase

Homocysteine1
methyltetrohydrofolote
methyltronsferose

I
/ M«BI2

/ N5-Me-FH4
I METHIONINEl

Figure XI
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Cystothionine
0 synthetase
CYSTATHIONINE

/ \
ICYSTEINEl

a-KETOBUTYRIC
ACID
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